Yargesa – Package Leaflet: InfoCons – Consumer Protection presents, in an accessible format, the official package leaflet of the medicine Yargesa, as authorised in the European Union and published in the Union Register of medicinal products.
Before anything else
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
ℹ️ 1. What Yargesa is and what it is used for
Yargesa contains the active substance miglustat which belongs to a group of medicines that affect metabolism. It is used to treat two conditions:
- Yargesa is used to treat mild to moderate type 1 Gaucher disease in adults.
In type 1 Gaucher disease, a substance called glucosylceramide is not removed from your body. It starts to build up in certain cells of the body’s immune system. This can result in liver and spleen enlargement, changes in the blood and bone disease.
The usual treatment for type 1 Gaucher disease is enzyme replacement therapy. Yargesa is only used when a patient is considered unsuitable for treatment with enzyme replacement therapy.
- Yargesa is also used to treat progressive neurological symptoms in Niemann -Pick type C disease in adults and in children.
If you have Niemann-Pick type C disease, fats such as glycosphingolipids build up in the cells of your brain.
This can result in disturbances in neurological functions such as slow eye movements, balance, swallowing, and memory, and in seizures.
Yargesa works by inhibiting the enzyme called ‘glucosylceramide synthase’ which is responsible for the first step in the synthesis of most glycosphingolipids.
⚠️ 2. What you need to know before you take Yargesa Do not take Yargesa
- if you are allergic to miglustat or any of the other ingredients of this medicine (listed in section 6)
Warnings and precautions
Talk to your doctor or pharmacist before taking Yargesa 21 • if you suffer from kidney disease
- if you suffer from liver disease Your doctor will perform the following tests before treatment and during treatment with Yargesa
- an examination to check the nerves in your arms and legs
- measurement of vitamin B12 levels
- monitoring growth if you are a child or adolescent with Niemann-Pick type C disease
- monitoring of blood platelet counts The reason for these tests is that some patients have had tingling or numbness in the hands and feet, or a decrease in body weight, while taking this medicine. The tests will help the doctor decide whether these effects are due to your disease or other existing conditions, or due to side effects of Yargesa (see section 4 for further details).
If you have diarrhoea, your doctor may ask you to change your diet to reduce your lactose and carbohydrate intake such as sucrose (cane sugar), or not to take Yargesa together with food, or to temporarily reduce your dose. In some cases the doctor may prescribe anti -diarrhoeal medicines such as loperamide. Cases of Crohn’s disease (an inflammatory disease affecting the gut) have been reported in patients with Niemann – Pick type C disease treated with Yargesa . If your diarrhoea does not respond to these measures, or if you have any other abdominal complaint, consult your doctor. In such case, your doctor may decide to conduct further investigations to determine if there is another cause of your symptoms .
Male patients should use reliable birth control methods during their treatment with Yargesa and for 3 months after finishing treatment.
Children and adolescents Do not give this medicine to children and adolescents (below 18 years old) with type 1 Gaucher disease because it is not known if it works in this disease.
Other medicines and Yargesa
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. Tell your doctor if you are taking medicines containing imiglucerase, which are sometimes used at the same time as Yargesa. They may lower the amount of Yargesa in your body.
Pregnancy, breast-feeding and fertility
You should not take Yargesa if you are pregnant or thinking of becoming pregnant. Your doctor can give you more information. You must use effective birth control while taking Yargesa. Do not breast -feed while you are taking Yargesa.
Male patients should use reliable birth control methods during their treatment with this medicine and for 3 months after finishing treatment.
If you are pregnant, breast feeding, think you may be pregnant or planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Driving and using machines
Yargesa may make you feel dizzy. Do not drive or use any tools or machines if you feel dizzy.
Yargesa contains sodium
This medicinal product contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially ‘sodium -free’.
💊 3. How to take Yargesa
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
Dose
- For type 1 Gaucher disease: For adults, the usual dose is one capsule (100 mg) three times a day(morning, afternoon and evening). This means a daily maximum of three capsules (300 mg) .
- For Niemann -Pick type C disease: For adults and adolescents (over 12 years old), the usual dose is two capsules (200 mg) three times a day (morning, afternoon and evening). This means a daily maximum of six capsules (600 mg).
For children less than 12 years old , your doctor will adjust the dose for Niemann-Pick type C disease.
If you have a problem with your kidneys you may receive a lower starting dose. Your doctor may reduce your dose, e.g., to one capsule (100 mg) once or twice a day, if you suffer from diarrhoea when taking Yargesa (see section 4). Your doctor will tell you how long your treatment will last.
To remove the capsule:
1. Separate at perforations 2. Peel back paper at arrows 3. Push product through foil Yargesa can be taken with or without food. You should swallow the whole capsule with a glass of water.
If you take more Yargesa than you should
If you take more capsules than you were told to, consult your doctor immediately. Miglustat has been used in clinical trials at doses up to 3000 mg: this caused decreases in white blood cells and other side effects similar to those described in section 4.
If you forget to take Yargesa
Take the next capsule at the usual time. Do not take a double dose to make up for a forgotten dose.
If you stop taking Yargesa
Do not stop taking this medicine without talking to your doctor.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
❗ 4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Most serious side effects Some patients have had tingling or numbness in the hands and feet (seen commonly). They could be signs of peripheral neuropathy, due to side effects of Yargesa or they could be due to existing conditions. Your doctor will perform some tests before and during treatment with Yargesa to assess this (see section 2).
If you do get any of these effects, please seek medical advice from your doctor as soon as possible.
If you get a slight tremor, usually trembling hands, seek medical advice from your doctor as soon as possible. The tremor often disappears without needing to stop the treatment. Sometimes your doctor will need to reduce the dose or stop Yargesa treatment to stop the tremor.
Very common effects (may affect more than 1 in 10 people) The most common side effects are diarrhoea, flatulence (wind), abdominal (stomach) pain, weight loss and decreased appetite.
If you do lose some weight when you start treatment with Yargesa don’t worry. People usually stop losing weight as treatment goes on.
Common effects (may affect up to 1 in 10 people) Common side effects of treatment include headache, dizziness, paraesthesia (tingling or numbness), abnormal coordination, hypoaesthesia (reduced sensation to touch), dyspepsia (heartburn), nausea (feeling sick), constipation and vomiting, swelling or discomfort in the abdomen (stomach) and thrombocytopenia (reduced levels of blood platelets). The neurological symptoms and thrombocytopenia could be due to the underlying disease.
Other possible side effects are muscular spasms or weakness, fatigue, chills and malaise, depression, difficulty sleeping, forgetfulness and reduced libido.
Most patients get one or more of these side effects, usually at the start of treatment or at intervals during treatment. Most cases are mild and disappear quite quickly. If any of these side effects cause problems, consult your doctor. He or she may reduce the dose of Yargesa or recommend other medicines to help control side effects.
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V.
By reporting side effects you can help provide more information on the safety of this medicine.
🌡️ 5. How to store Yargesa
Keep this medicine out of the sight and reach of children.
Do not take this medicine after the expiry date which is stated on the blister and carton after ‘EXP’. The expiry date refers to the last day of that month.
Do not store above 25°C.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer take. These measures will help protect the environment.
📦 6. Contents of the pack and other information
What Yargesa contains
- the active substance is miglustat. Each hard capsule contains 100 mg miglustat.
- the other ingredients are: capsule content: sodium starch glycolate (type A), povidone (K -29/32), magnesium stearate capsule shell: gelatin, titanium dioxide (E171) printing ink: shellac, iron oxide black (E172), propylene glycol, concentrated ammonia solution
What Yargesa looks like and contents of the pack
Yargesa is a white hard capsule that consists of an opaque white cap and body with “708” printed in black on the body. Capsule size is 4 (14.3 mm x 5.3 mm). The capsules are presented in a PVC and polychlorotrifluoroethylene (PCTFE) perforated unit dose bl ister sealed with aluminium foil.
Pack size of 84 x 1 hard capsules.
Marketing Authorisation Holder and Manufacturer
Piramal Critical Care B.V. Rouboslaan 32 (ground floor) 2252 TR, Voorschoten The Netherlands
This leaflet was last revised in
Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
📄 Package Leaflet – official source
This article reproduces the information in the official package leaflet, as authorised in the European Union. You can consult the original document here: Product information Yargesa (PDF, ec.europa.eu).
You can check this medicine at any time in the Union Register of medicinal products (EU number EU/1/17/1176).
⚠️ Important: This article is for information purposes only and does not replace medical advice or the package leaflet inside the medicine box. Read the leaflet carefully before use. For any questions about your treatment, talk to your doctor or pharmacist. If you experience side effects, tell your doctor or pharmacist and report them through your national reporting system.